

Sensory Neuropathy of The Foot Among Asymptomatic Patients of Type II Diabetes Mellitus

Syed Mazhar Ali Shah¹, Muhammad Bilal^{1*}, Saima Khattak¹, Mian Fareezuddin², Yaseen Khan¹

¹Lady Reading Hospital, Peshawar, KPK-Pakistan

²Health Department, Federal Public Service Commission, Peshawar, KPK-Pakistan

Correspondence: drmba@yahoo.com

doi: 10.22442/jlumhs.2024.01097

ABSTRACT

OBJECTIVE: This Study aimed to determine the frequency of sensory neuropathy in the feet of asymptomatic people with type II diabetes mellitus.

METHODOLOGY: This cross-sectional Study was conducted at the medical department of MTI/Lady Reading Hospital, Peshawar, between April 25, 2022, and October 25, 2022. A total of 133 patients were observed using a non-probability consecutive sampling technique. Patients aged 25-60 years who had type II diabetes mellitus for more than one year were included, while patients with vitamin B12 deficiency who used multivitamins were excluded from the study. SPSS version 20 was used for statistical analysis.

RESULTS: Age-wise distribution 25-30 Years (4.5%), 31-40 Years (21.8%), 41-50 Years (45.9%), and 51-60 Years (27.8%) (mean 45.56±3.3). Gender-wise, 104 (78.2%) were male and 29 (21.8%) were female. Regarding education level, 57 (42.9%) were illiterate, 46 (34.6%) had secondary education, and 30 (22.6%) had higher education. Residency status indicated 105 (78.9%) from urban areas and 28 (21.1%) from rural areas. Socioeconomic status was distributed as follows: 53 (39.8%) with a monthly income >100,000 Rs, 46 (34.6%) with an income range of 50,000 to 100,000 Rs, and 34 (25.6%) with an income range <50,000 Rs. Sensory neuropathy was found in 60 (45.1%) patients and absent in 73 (54.9%).

CONCLUSION: The Study revealed a notably high prevalence of sensory neuropathy. Prompt identification and focused treatment are essential, especially for patients over 40, sedentary lifestyles, and those with diabetes for more than two years.

Keywords: Asymptomatic Patients, Foot, Peripheral Neuropathy, Sedentary Lifestyles, Sensory Neuropathy, Type II Diabetes Mellitus.

INTRODUCTION

Diabetes mellitus has become a worldwide health emergency, posing a complex challenge that is made worse by the current spike in obesity rates¹. Due to its widespread effects, diabetes is currently the seventh most common cause of death globally². The toll is particularly noticeable in the US, where it was responsible for an astounding 252,806 fatalities in 2015 alone³. Beyond its immediate consequences, diabetes dramatically increases the risk of cardiovascular diseases (CVD), which eventually emerges as the leading cause of death for those with the diagnosis⁴. Peripheral neuropathy specifically, sensory neuropathy of the foot—is one of the many problems closely associated with diabetes^{5,6}.

Diabetes mellitus is a group of metabolic diseases typified by prolonged increases in blood sugar levels⁷. These elevated blood sugar levels can lead to several unfavourable health consequences, including peripheral neuropathy, renal failure, and cardiovascular problems⁸. It is noteworthy that the number of people affected by diabetes has increased to an alarming 382 million globally⁹. This worry is highlighted by projections, which indicate that by 2035, there will be an increase to 592 million instances¹⁰.

Although weight loss, increased thirst, increased appetite, and frequent urination are the classic symptoms of diabetes, this study focuses on the complex field of peripheral neuropathy, specifically sensory neuropathy affecting the lower extremities¹¹. Diabetic neuropathy is common; about 30–40% of people with diabetes have this condition. It can cause symptoms such as tingling, numbness, and excruciating pain¹². The increasing prevalence of diabetes worldwide predicts a worsening of neuropathy-related costs. Hence, its frequency and consequences should be thoroughly studied¹³.

Up to 25% of people with diabetes have painful diabetic peripheral neuropathy (painful-dpn), which can significantly reduce the quality of life¹⁴. People with painful-dpn can present with varying degrees of persistent burning, aching, and "electric shock" pains in their legs and feet¹⁵. Nighttime exacerbations and contact hypersensitivity to bedclothes cause sleeplessness, and painful-dpn can be incapacitating¹⁶. The primary stay of treatment for painful-dpn is symptom control with pharmacotherapy, which has limited efficacy and frequently dose-limiting side effects⁸. The symptoms of painful-dpn include loss of sensation, weakness, and pain¹⁷. The pathophysiology of painful DPN is poorly understood, and no disease-modifying treatments exist for DPN¹⁸. About 30–40% of people with diabetes also have DPN, and as the global incidence of diabetes continues to rise, so too will the burden of this condition¹⁹. DPN is a crippling complication that has a significant influence on healthcare services in addition to the patient's quality of life²⁰. Patients with type II diabetes mellitus have reported DPN prevalence rates of 39.5%²¹.

The frequency and effects of sensory neuropathy of the foot in asymptomatic people with type II diabetes mellitus are still largely unknown, especially when it comes to local populations, despite the abundance of research on diabetic sequelae²². By offering thorough insights into the prevalence of this crippling issue, this study aims to close this critical gap and provide the foundation for future research projects and preventive measures. Formulating targeted therapies to reduce the morbidity and mortality associated with sensory neuropathy requires a sophisticated understanding of the local prevalence rates and related risk factors.

METHODOLOGY

This descriptive cross-sectional design study was conducted in the General Medical Department of Lady Reading Hospital in Peshawar from April to October 2022 after ethical acceptance from the institute. With a 5.2% margin of error and a 10.4% prevalence of diabetic peripheral neuropathy (DPN) among patients with type II diabetes mellitus, 133 individuals were chosen using the WHO criteria. Non-probability sequential sampling was used.

Participants in the Study were required to meet specified inclusion criteria, which included being between the ages of 25 and 60, having a diagnosis of type II diabetes mellitus for more than one year, being gender-neutral, and having no glycaemic control status. Patients who met the exclusion criteria included those who, based on their medical history and records, had been diagnosed with vitamin B12 insufficiency, had pre-existing neuropathy, or took multivitamin supplements.

Patients who fit the criteria were sourced from the general medical department and outpatients with ethical permission from the hospital's research committee. After outlining the goals and advantages of the study, informed consent was obtained. A thorough history was taken, along with clinical exams, baseline investigations, and measurement of HbA1C. Semmes-Weinstein (SW) monofilament testing was performed on foot locations to identify sensory neuropathy. The test was deemed successful if the patient did not feel the touch of the monofilament at any of the predetermined locations.

Data were collected on a predefined proforma that included a variety of factors, including demographics, medical history, and socioeconomic status, to ensure adherence to the exclusion criteria and reduce bias. SPSS version 20 was used to enter the recorded data and perform statistical analysis. For numerical variables, descriptive statistics calculated the mean \pm SD; categorical variables calculated frequencies/percentages. Stratification of sensory neuropathy with modifiers such as age, gender, and other variables was examined to assess any effect modifications ($p < 0.05$) using chi-square tests. Tables and graphs were used to show the results and provide a thorough understanding of the correlation between different variables and the prevalence of sensory neuropathy.

RESULTS

The demographic distribution and salient features of the research participants are illustrated in the **Table I**. It shows how people are distributed across the various age groups, with the 41–50-year-old age group having the highest percentage (45.9%), followed by the 51–60-year-old group (27.8%). Male participants comprised 78.2% of the sample, while female participants comprised 21.8%. When compared to individuals whose disease had been diagnosed for more than two years (21.1%), a more significant percentage of people with diabetes had just been diagnosed for one to two years (78.9%). Furthermore, the distribution of the participant's Body Mass Index (BMI) revealed a prevalence of those falling into the obese range (30.1%) and the overweight range (45.9%). According to residency status, more people lived in cities (78.9%) than in rural areas (21.1%). The distribution of educational attainment showed that a significant number had completed secondary school (34.6%), closely followed by those classified as illiterate (42.9%) and those with a higher degree of education (22.6%). Furthermore, there was an excellent representation of the socioeconomic category in the rich income group (>100,000 Rs) at 39.8%, with the middle-income range coming in second (34.6%).

Table I: Demographic details of the participants

Variable	Detail	Frequency	Percentage
Age of the participants	25- 30 Years	6	4.5
	31-40 Years	29	21.8
	41-50 Years	61	45.9
	51-60 Years	37	27.8
Gender wise distribution	Male	104	78.2
	Female	29	21.8
Duration of disease-wise distribution	1 to 2 Years	105	78.9
	More than 2 Years	28	21.1
Bmi classification	Underweight range	5	3.8
	Normal range	27	20.3
	Overweight range	61	45.9
	Obese range	40	30.1
Residency status	Urban	105	78.9
	Rural	28	21.1
Education level	Illiterate	57	42.9
	Secondary education	46	34.6
	Higher education	30	22.6
Distribution of residency status	Urban	105	78.9
	Rural	28	21.1
Distribution of socioeconomic status	Rich (monthly income >100,000 Rs)	53	39.8
	Middle Class (monthly income range 50,000 – 100,000 Rs)	46	34.6

Important information about the study participants' hypertension, sensory neuropathy, and family history of diabetes mellitus is shown in **Table II**. Of the participants, 45.1% showed evidence of sensory neuropathy, whereas the majority, 54.9%, showed no signs of the condition. Concerning hypertension, a sizeable fraction of participants - 60.2% of the sample were found to have it, although 39.8% did not exhibit any symptoms. With 46.6% of participants having a family history of diabetes and 53.4% having no family history of diabetes (non-diabetic), the distribution of family history of diabetes mellitus showed a virtually balanced representation. These numbers highlight how common it is for study participants to have a familial predisposition for diabetes, suggesting that genetic variables play a significant role in this cohort.

Table II: Frequencies and percentages of different diseases of the participants

Variable	Detail	Frequency	Percentage
Sensory neuropathy	Yes	60	45.1
	No	73	54.9
Distribution of hypertension	Yes	80	60.2
	No	53	39.8
Distribution of family history of diabetes mellitus	Non Diabetic	71	53.4
	Diabetic	62	46.6

Table III presents the significant statistical connections shown by the p-values between several variables and the occurrence of sensory neuropathy in the study subjects. Age distribution showed that 31 people between 41 and 50 had sensory neuropathy, while only three were unaffected, demonstrating a significant correlation ($p = 0.000$). On the other hand, the age range of 51 to 60 years old showed the opposite pattern, with most of the 37 afflicted and unaffected. There was also a noteworthy correlation between gender and sensory neuropathy, with men showing a higher incidence of the condition than women ($p = 0.0334$). A statistically significant correlation was found in the distribution of sensory neuropathy across different BMI categories. The effects on individuals were significantly more significant in the overweight and obese categories than in the normal and underweight ranges ($p = 0.000$). There was a statistically significant correlation ($p = 0.000$) between the prevalence of sensory neuropathy in illiterate persons and those who had completed secondary or higher education. Socioeconomic status also showed a significant correlation, with a higher prevalence of sensory neuropathy in those from richer and middle-class backgrounds than in those from lower-class backgrounds ($p = 0.000$). Additionally, there were significant correlations between sensory neuropathy and family histories of diabetes mellitus and hypertension. Specifically, people with a history of diabetes or hypertension had a higher prevalence of sensory neuropathy than people without such a history ($p = 0.000$).

Table III: Association of sensory neuropathy with different variables

Variable	Detail	Sensory Neuropathy		P-value
		Yes	No	
Age of the participants	25- 30 Years	5	1	0.000
	31-40 Years	24	5	
	41-50 Years	31	3	
	51-60 Years	0	37	
Gender of the participants	Male	58	46	0.0334
	Female	2	27	
Duration of disease	1-2 years	60	45	0.672
	More than 2 years	0	28	
BMI classification	Underweight range	5	0	0.000
	Normal range	24	3	
	Overweight range	31	30	
	Obese range	0	40	
Residency status	Urban	60	45	0.00
	Rural	0	28	
Education level	Illiterate	44	13	0.000
	Secondary education	0	46	
	Higher education	16	14	
Socioeconomic status	Rich (monthly income > 100, 000 Rs)	44	9	0.000
	Middle Class (monthly 50,000 - 100,000 Rs)	0	46	
	Low income (< 50,000 Rs)	16	18	
Family history of diabetes mellitus	Yes	60	11	0.000
	No	0	62	
Hypertension	Yes	60	20	0.000
	No	0	53	

DISCUSSION

The age distribution of the 133 patients in the current study was examined, yielding n = 25-30 Years 6(4.5%), 31-40 Years: 29(21.8%), 41-50 Years: 61(45.9%), 51-60 Years: 37(27.8%), 45.56 years was the mean age, with a standard deviation of ± 3.357 . The analysis of the 133 patients' gender distribution revealed that 104(78.2%) were male and 29(21.8%) were female. Analysis of 133 patients' educational levels showed that 57(42.9%) were illiterate. 46(34.6%) secondary education Higher learning 30(22.6%), 133 patients residency status distribution was analyzed, and the results showed that n= Urban 105(78.9%), rural areas 28(21.1%). The socioeconomic status distribution of 133 patients was examined, and it was found that n= Rich (monthly income >100,000 Rs). 53(39.8%) Class C: Middle (monthly income between 50,000 and 100,000 rupees) 46(34.6%) Low income (monthly income < 50,000 Rs.) 34(25.6%). 133 patients with sensory neuropathy were analyzed, with 60(45.1%) with Yes and 73(54.9%) with No findings. The results of our investigation show that the prevalence of DPN, as reported by the MNSI history version, was 18.9%, significantly less than the 51.1% prevalence obtained by the MNSI examination of the same study. This discrepancy highlights the limitations of how patients perceive their own DPN symptoms and advocates for using the examination version of the MNSI. Based on MNSI, 196(53.6%) of the 366 patients in the study had an overall DPN prevalence (95% CI 48.9, 59). Our findings were consistent with a 52.2% study conducted in Bahirdar, Ethiopia²³. The current study's prevalence also agreed with reports from other nations, such as Yemen, the USA, Ghana, and Malaysia, where it was determined to be 56.2%, 51%, 50.7%, and 50.7%²⁴. The similarity in research design between the studies conducted in Yemen and Malaysia and the results obtained in Bahirdar, the USA, and Ghana may have resulted from using the same instrument²⁵.

However, the current study's findings exceeded those of a 39.5% study done in Jordan²⁶. This variation may result from variations in healthcare attributes and genetic predisposition. Similarly, a study in China revealed a 33.1% frequency of DPN²⁷. The community under investigation, genetic predisposition, and varied medical care availability could all contribute to the greater DPN prevalence rate that we found in our study. Furthermore, research from Mulago, Uganda, 29.5%²⁸ and Libya, 30.5%²⁹ indicate a lower prevalence of DPN. These disparities in prevalence are probably due to variations in the study population, the diagnostic standards applied, and the participant selection procedures.

According to reports, Jimma, Ethiopia, had a prevalence of 25.4% and Mekelle, Ethiopia, 41%, respectively, of diabetic peripheral neuropathy³⁰. The difference in DPN prevalence between our Study and Mekelle may be due to the later use of a prospective cohort study with a six-week period that only records new cases. Type 1 and type 2 diabetes were included in the previous study that Jimma published; the sample size was small, and the data on DPN came from a review of patient charts. DPN may not have been frequently documented on the patient chart during follow-up, which might be why the preceding study lacks DPN cases. This study evaluated DPN using the MNSI history and examination versions, which can find more cases³⁰. There was a decreased prevalence of DPN when the current study was compared to studies from Iran, Nigeria, and Italy, which found DPN prevalence of 75.1%, 75%, and 82%, respectively³¹. The greater frequency of those studies may result from different research designs, settings, and tools utilized. While the Nigerian study utilized a vibration perception threshold instrument of greater than 15 volts, which may have inflated the prevalence of DPN, the Iranian Study used nerve conduction velocity, the gold standard test, and a large sample size³². Lastly, the disparity between the present study's findings and an Italian study might be explained by variations in study design, genetic predisposition, and instrumentation³³.

The present results showed that the patient's age over 40 was a reliable indicator of DPN. Studies from the past provided support for this report³⁴. Potential explanations for this correlation could be supported by the fact that peripheral neuropathy is a chronic diabetes consequence that develops gradually, making older diabetic individuals more likely to have it. Furthermore, as people age, their neural systems become more susceptible to ongoing metabolic stress and the deteriorating effects of aging on their bodies³⁵.

Our research revealed a substantial correlation between DPN and DM, lasting more than five years. A similar conclusion was also stated in several study findings²⁶. The prolonged duration of diabetes is associated with chronic hyperglycemia, which triggers many metabolic pathways in diabetic neurons, leading to oxidative stress and subsequent neuronal ischemia and nerve damage, which explains the linkage³⁵. The possibility of a delayed diagnosis can also explain it.

Consistent with previous findings, our data demonstrated that lack of physical activity was identified as a separate factor predicting diabetic peripheral neuropathy (DPN)³⁶. One possible explanation for this correlation could be that engaging in physical activity can enhance the circulation of small blood vessels, promote the production of neurotrophic factors, reduce oxidative stress, and contribute to the overall physiological well-being of the body³⁷.

Ultimately, the current investigation established a noteworthy correlation between the act of smoking and the occurrence of diabetic peripheral neuropathy (DPN). Other investigations have also reported similar findings³⁵. The relationship between DPN and smoking can be explained by the fact that smoking causes neuropathy using endothelial damage, increased inflammation, oxidative stress, alteration of glucose metabolism, and direct neurotoxic effects that cause neuronal ischemia.

CONCLUSION

The high frequency of DPN in our study was quite considerable. For individuals who are older than 40, are not physically active, and have had diabetes for more than two years, early detection and suitable therapies are crucial.

Ethical permission: Lady Ready Hospital, Medical Teaching Institute ERB letter No. 115/LRH.

Conflict of Interest: No conflicts of interest, as stated by authors.

Financial Disclosure / Grant Approval: No funding agency was involved in this research.

Data Sharing Statement: The corresponding author can provide the data proving the findings of this study on request. Privacy or ethical restrictions bound us from sharing the data publicly.

AUTHOR'S CONTRIBUTION

Shah SMA: Study design and conceptualization, data collection, approval of manuscript

Bilal M: Study design and conceptualization, data analysis, manuscript revising and drafting, approval of manuscript

Khattak S: Data analysis, manuscript revising and drafting, approval of manuscript

Fareezuddin M: Data collection, manuscript drafting and revising, approval of manuscript

Khan Y: Data analysis, data collection, approval of manuscript

REFERENCES

1. Jha BK, Sherpa ML, Imran M. Progress in understanding metabolic syndrome and knowledge of its complex pathophysiology. *Diabetology*. 2023; 4(2): 134-59.
2. Khan MAB, Hashim MJ, King JK. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. *J Epidemiol Glob Health*. 2020; 10(1): 107-11. doi: 10.2991/jegh.k.191028.001
3. Basiri R, Seidu B, Rudich M. Exploring the interrelationships between diabetes, nutrition, anxiety, and depression: Implications for treatment and prevention strategies. *Nutrients*. 2023; 15(19). doi: 10.3390/nu15194226.
4. Jyotsna F, Ahmed A, Kumar K. Exploring the complex connection between diabetes and cardiovascular disease: Analyzing approaches to mitigate cardiovascular risk in patients with diabetes. *Cureus*. 2023; 15(8): e43882. doi: 10.7759/cureus.43882
5. Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. *Curr Diab Rep*. 2019; 19(10): 86. doi: 10.1007/s11892-019-1212-8
6. Aleidan FAS, Ahmad BA, Alotaibi FA. Prevalence and risk factors for diabetic peripheral neuropathy among Saudi hospitalized diabetic patients: A nested case-control study. *Int J Gen Med*. 2020; 13: 881-9. doi: 10.2147/ijgm.S273807
7. Agunloye OM, Oboh G. Blood glucose lowering and effect of oyster (*Pleurotus ostreatus*)-and shiitake (*Lentinus subnudus*)-supplemented diet on key enzymes linked diabetes and hypertension in streptozotocin-induced diabetic in rats. *Food Frontiers*. 2022; 3(1): 161-71
8. Sacchetta L, Chiriaco M, Nesti L. Synergistic effect of chronic kidney disease, neuropathy, and retinopathy on all-cause mortality in type 1 and type 2 diabetes: A 21-year longitudinal study. *Cardiovascular Diabetology*. 2022; 21(1): 233. doi: 10.1186/s12933-022-01675-6
9. Azeem S, Khan U, Liaquat A. The increasing rate of diabetes in Pakistan: A silent killer. *Ann Med Surg (Lond)*. 2022; 79: 103901. doi: 10.1016/j.amsu.2022.103901
10. Saeedi P, Petersohn I, Salpea P. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes atlas, 9(th) edition. *Diabetes Res Clin Pract*. 2019; 157: 107843. doi: 10.1016/j.diabres.2019.107843
11. Sambyal N, Saini P, Syal R. A review of statistical and machine learning techniques for microvascular complications in type 2 diabetes. *Current Diabetes Reviews*. 2021; 17(2): 143-55
12. Feldman EL, Callaghan BC, Pop-Busui R. Diabetic neuropathy. *Nat Rev Dis Primers*. 2019; 5(1): 42. doi: 10.1038/s41572-019-0097-9
13. Carmichael J, Fadavi H, Ishibashi F. Advances in screening, early diagnosis and accurate staging of diabetic neuropathy. *Front Endocrinol (Lausanne)*. 2021;12:671257. doi: 10.3389/fendo.2021.671257
14. Chang MC, Yang S. Diabetic peripheral neuropathy essentials: A narrative review. *Annals of Palliative Medicine*. 2023; 12(2): 390-8
15. Akter N. Diabetic peripheral neuropathy: Epidemiology, physiopathology, diagnosis and treatment. *Delta Medical College Journal*. 2019; 7(1): 35-48
16. Sloan G, Shillo P, Selvarajah D. A new look at painful diabetic neuropathy. *Diabetes research and clinical practice*. 2018; 144: 177-91
17. Azmi S, ElHadd KT, Nelson A. Pregabalin in the management of painful diabetic neuropathy: A narrative review. *Diabetes Ther*. 2019; 10(1): 35-56. doi: 10.1007/s13300-018-0550-x

18. Yang H, Sloan G, Ye Y. New perspective in diabetic neuropathy: From the periphery to the brain, a call for early detection, and precision medicine. *Front Endocrinol (Lausanne)*. 2019; 10: 929. doi: 10.3389/fendo.2019.00929
19. The burden of chronic respiratory diseases and their heterogeneity across the states of India: The global burden of disease study 1990-2016. *Lancet Glob Health*. 2018; 6(12): e1363-e74. doi: 10.1016/s2214-109x(18)30409-1
20. Ghammari F, Khodayari-zarnaq R, Jalilian H, Gholizadeh M. Barriers to health care utilization among patients with type 2 diabetes living in slums: A qualitative study from providers' perspective. *Global Health Research and Policy*. 2023; 8(1): 13. doi: 10.1186/s41256-023-00296-0
21. Ponirakis G, Elhadd T, Al Ozairi E. Prevalence and risk factors for diabetic peripheral neuropathy, neuropathic pain and foot ulceration in the Arabian Gulf region. *J Diabetes Investig*. 2022; 13(9): 1551-9. doi: 10.1111/jdi.13815
22. Syed O, Jancic P, Knezevic NN. A review of recent pharmacological advances in the management of diabetes-associated peripheral neuropathy. *Pharmaceuticals*. 2023; 16(6): 801
23. Laios K, Karamanou M, Saridaki Z, Androutsos G. Aretaeus of Cappadocia and the first description of diabetes. *Hormones (Athens)*. 2012; 11(1): 109-13. doi: 10.1007/bf03401545
24. Vural B, Caliskan E, Turkoz E. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. *Hum Reprod*. 2005; 20(9): 2409-13. doi: 10.1093/humrep/dei100
25. Abdissa D, Hamba N, Kene K. Prevalence and determinants of peripheral neuropathy among type 2 adult diabetes patients attending jimma university medical center, southwest Ethiopia, 2019, an institutional-based cross-sectional study. *J Diabetes Res*. 2020; 2020: 9562920. doi: 10.1155/2020/9562920
26. Imam SK, Shahid SK, Hassan A, Alvi Z. Frequency of the metabolic syndrome in type 2 diabetic subjects attending the diabetes clinic of a tertiary care hospital. *J Pak Med Assoc*. 2007; 57(5): 239-42
27. Fawwad A, Qasim R, Hydrie MZ. Correlation of fasting insulin resistance indices, clinical parameters of metabolic syndrome in type 2 diabetics. *Pakistan Journal of Medical Sciences Online*. 2006; 22: 433-7
28. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. *Jama*. 2002; 287(19): 2570-81. doi: 10.1001/jama.287.19.2570
29. Laing SP, Swerdlow AJ, Slater SD. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. *Diabetologia*. 2003; 46(6): 760-5. doi: 10.1007/s00125-003-1116-6
30. Paterson AD, Rutledge BN, Cleary PA. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: The diabetes control and complications trial/epidemiology of diabetes interventions and complications study. *Diabetes Care*. 2007; 30(8): 2107-12. doi: 10.2337/dc06-1441
31. Buse JB, Ginsberg HN, Bakris GL. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American diabetes association. *Diabetes Care*. 2007; 30(1): 162-72. doi: 10.2337/dc07-9917
32. Liu M, Gao Y, Chen DW. Quantitative vibration perception threshold in assessing diabetic polyneuropathy: Should the cut-off value be adjusted for Chinese individuals with type 2 diabetes? *J Diabetes Investig*. 2021; 12(9): 1663-70. doi: 10.1111/jdi.13515

33. Henriksen MG, Nordgaard J, Jansson LB. Genetics of schizophrenia: Overview of methods, findings and limitations. *Front Hum Neurosci.* 2017; 11: 322. doi: 10.3389/fnhum.2017.00322
34. Qiao Q. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. *Diabetologia.* 2006; 49(12): 2837-46. doi: 10.1007/s00125-006-0438-6
35. Avogaro A, Giorda C, Maggini M. Incidence of coronary heart disease in type 2 diabetic men and women: Impact of microvascular complications, treatment, and geographic location. *Diabetes Care.* 2007; 30(5): 1241-7. doi: 10.2337/dc06-2558
36. Nathan DM, Buse JB, Davidson MB. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American diabetes association and the European Association for the Study of Diabetes. *Diabetes Care.* 2006; 29(8): 1963-72. doi: 10.2337/dc06-9912
37. Sjöström L, Lindroos AK, Peltonen M. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med.* 2004; 351(26): 2683-93. doi: 10.1056/NEJMoa035622